177 related articles for article (PubMed ID: 38339343)
81. Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications.
Jara-Acevedo M; Teodosio C; Sanchez-Muñoz L; Álvarez-Twose I; Mayado A; Caldas C; Matito A; Morgado JM; Muñoz-González JI; Escribano L; Garcia-Montero AC; Orfao A
Mod Pathol; 2015 Aug; 28(8):1138-49. PubMed ID: 26067933
[TBL] [Abstract][Full Text] [Related]
82. Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens.
Mayerhofer M; Gleixner KV; Hoelbl A; Florian S; Hoermann G; Aichberger KJ; Bilban M; Esterbauer H; Krauth MT; Sperr WR; Longley JB; Kralovics R; Moriggl R; Zappulla J; Liblau RS; Schwarzinger I; Sexl V; Sillaber C; Valent P
J Immunol; 2008 Apr; 180(8):5466-76. PubMed ID: 18390729
[TBL] [Abstract][Full Text] [Related]
83. A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection.
Saleh R; Wedeh G; Herrmann H; Bibi S; Cerny-Reiterer S; Sadovnik I; Blatt K; Hadzijusufovic E; Jeanningros S; Blanc C; Legarff-Tavernier M; Chapiro E; Nguyen-Khac F; Subra F; Bonnemye P; Dubreuil P; Desplat V; Merle-Béral H; Willmann M; Rülicke T; Valent P; Arock M
Blood; 2014 Jul; 124(1):111-20. PubMed ID: 24677542
[TBL] [Abstract][Full Text] [Related]
84. Antineoplastic efficacy profiles of avapritinib and nintedanib in
Degenfeld-Schonburg L; Gamperl S; Stefanzl G; Schruef AK; Sadovnik I; Bauer K; Smiljkovic D; Eisenwort G; Peter B; Greiner G; Hadzijusufovic E; Schwaab J; Sperr WR; Hoermann G; Kopanja S; Szépfalusi Z; Hoetzenecker K; Jaksch P; Reiter A; Arock M; Valent P
Am J Cancer Res; 2023; 13(2):355-378. PubMed ID: 36895976
[TBL] [Abstract][Full Text] [Related]
85. KIT Mutations and Other Genetic Defects in Mastocytosis: Implications for Disease Pathology and Targeted Therapies.
Chantran Y; Valent P; Arock M
Immunol Allergy Clin North Am; 2023 Nov; 43(4):651-664. PubMed ID: 37758404
[TBL] [Abstract][Full Text] [Related]
86. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis.
Wilson TM; Maric I; Simakova O; Bai Y; Chan EC; Olivares N; Carter M; Maric D; Robyn J; Metcalfe DD
Haematologica; 2011 Mar; 96(3):459-63. PubMed ID: 21134978
[TBL] [Abstract][Full Text] [Related]
87. Mastocytosis: pathology, genetics, and current options for therapy.
Valent P; Akin C; Sperr WR; Mayerhofer M; Födinger M; Fritsche-Polanz R; Sotlar K; Escribano L; Arock M; Horny HP; Metcalfe DD
Leuk Lymphoma; 2005 Jan; 46(1):35-48. PubMed ID: 15621779
[TBL] [Abstract][Full Text] [Related]
88. Detection of the c-kit D816V mutation in systemic mastocytosis by allele-specific PCR.
Schumacher JA; Elenitoba-Johnson KS; Lim MS
J Clin Pathol; 2008 Jan; 61(1):109-14. PubMed ID: 17526803
[TBL] [Abstract][Full Text] [Related]
89. Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis.
Lübke J; Schwaab J; Naumann N; Horny HP; Weiß C; Metzgeroth G; Kreil S; Cross NCP; Sotlar K; Fabarius A; Hofmann WK; Valent P; Gotlib J; Jawhar M; Reiter A
J Clin Oncol; 2022 Jun; 40(16):1783-1794. PubMed ID: 35235417
[TBL] [Abstract][Full Text] [Related]
90. Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation.
Jin Y; Ding K; Wang D; Shen M; Pan J
Cancer Lett; 2014 Oct; 353(1):115-23. PubMed ID: 25088577
[TBL] [Abstract][Full Text] [Related]
91. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
Pan J; Quintás-Cardama A; Kantarjian HM; Akin C; Manshouri T; Lamb P; Cortes JE; Tefferi A; Giles FJ; Verstovsek S
Blood; 2007 Jan; 109(1):315-22. PubMed ID: 16912224
[TBL] [Abstract][Full Text] [Related]
92. Oncogenic D816V-KIT signaling in mast cells causes persistent IL-6 production.
Tobío A; Bandara G; Morris DA; Kim DK; O'Connell MP; Komarow HD; Carter MC; Smrz D; Metcalfe DD; Olivera A
Haematologica; 2020 Jan; 105(1):124-135. PubMed ID: 30948489
[TBL] [Abstract][Full Text] [Related]
93. Case Report: Evolution of
Sciumè M; Ceparano G; Eller-Vainicher C; Fabris S; Lonati S; Croci GA; Baldini L; Grifoni FI
Front Oncol; 2021; 11():734025. PubMed ID: 34917498
[TBL] [Abstract][Full Text] [Related]
94. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.
Sotlar K; Bache A; Stellmacher F; Bültmann B; Valent P; Horny HP
J Mol Diagn; 2008 Jan; 10(1):58-66. PubMed ID: 18165278
[TBL] [Abstract][Full Text] [Related]
95. Perceptions of patient disease burden and management approaches in systemic mastocytosis: Results of the TouchStone Healthcare Provider Survey.
Mesa RA; Sullivan EM; Dubinski D; Carroll B; Slee VM; Jennings SV; Finnerty CC; Bohannon LS; Mathias SD; Lahue BJ; Castells MC
Cancer; 2022 Oct; 128(20):3700-3708. PubMed ID: 35996871
[TBL] [Abstract][Full Text] [Related]
96. Relocalization of KIT D816V to cell surface after dasatinib treatment: potential clinical implications.
Bougherara H; Georgin-Lavialle S; Damaj G; Launay JM; Lhermitte L; Auclair C; Arock M; Dubreuil P; Hermine O; Poul MA
Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):62-9. PubMed ID: 23127495
[TBL] [Abstract][Full Text] [Related]
97. KIT(D816V+) systemic mastocytosis associated with KIT(D816V+) acute erythroid leukaemia: first case report with molecular evidence for same progenitor cell derivation.
McClintock-Treep SA; Horny HP; Sotlar K; Foucar MK; Reichard KK
J Clin Pathol; 2009 Dec; 62(12):1147-9. PubMed ID: 19729359
[TBL] [Abstract][Full Text] [Related]
98. The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation.
Jin Y; Lu Z; Cao K; Zhu Y; Chen Q; Zhu F; Qian C; Pan J
Mol Cancer Ther; 2010 Jan; 9(1):211-23. PubMed ID: 20053766
[TBL] [Abstract][Full Text] [Related]
99. Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis.
Reiter A; Schwaab J; DeAngelo DJ; Gotlib J; Deininger MW; Pettit KM; Alvarez-Twose I; Vannucchi AM; Panse J; Platzbecker U; Hermine O; Dybedal I; Lin HM; Rylova SN; Ehlert K; Dimitrijević S; Radia DH
Blood Adv; 2022 Nov; 6(21):5750-5762. PubMed ID: 35640224
[TBL] [Abstract][Full Text] [Related]
100. European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis.
Tzogani K; Yu Y; Meulendijks D; Herberts C; Hennik P; Verheijen R; Wangen T; Dahlseng Håkonsen G; Kaasboll T; Dalhus M; Bolstad B; Salmonson T; Gisselbrecht C; Pignatti F
ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32392175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
